

Lung service profiles – a short overview















































































Sean McPhail

Senior Analyst & Profiles Technical Lead

Discuss...

- Lung service profiles: rationale, process, structure
- Specialist lung profiles (briefly): going forward

A PERIODIC TABLE OF VISUALIZATION METHODS

<div><div></div><div>C</div><div>continuum</div></div>	<div><div></div><div>Data Visualization Visual representations of quantitative data in schematic form (either with or without axes)</div></div> <div><div></div><div>Strategy Visualization The systematic use of complementary visual representations in the analysis, development, formulation, communication, and implementation of strategies in organizations.</div></div>										<div><div></div><div>G</div><div>graphic facilitation</div></div>						
<div><div></div><div>Tb</div><div>table</div></div>	<div><div></div><div>Ca</div><div>cartesian coordinates</div></div>	<div><div></div><div>Information Visualization The use of interactive visual representations of data to amplify cognition. This means that the data is transformed into an image, it is mapped to screen space. The image can be changed by users as they proceed working with it</div></div> <div><div></div><div>Metaphor Visualization Visual Metaphors position information graphically to organize and structure information. They also convey an insight about the represented information through the key characteristics of the metaphor that is employed</div></div>										<div><div></div><div>Me</div><div>meeting trace</div></div>	<div><div></div><div>Mm</div><div>metro map</div></div>	<div><div></div><div>Tm</div><div>temple</div></div>	<div><div></div><div>St</div><div>story template</div></div>	<div><div></div><div>Tr</div><div>tree</div></div>	<div><div></div><div>Ct</div><div>cartoon</div></div>
<div><div></div><div>Pi</div><div>pie chart</div></div>	<div><div></div><div>L</div><div>line chart</div></div>	<div><div></div><div>Concept Visualization Methods to elaborate (mostly) qualitative concepts, ideas, plans, and analyses.</div></div> <div><div></div><div>Compound Visualization The complementary use of different graphic representation formats in one single schema or frame</div></div>										<div><div></div><div>Co</div><div>communication diagram</div></div>	<div><div></div><div>Fp</div><div>flight plan</div></div>	<div><div></div><div>Cs</div><div>concept sceleton</div></div>	<div><div></div><div>Br</div><div>bridge</div></div>	<div><div></div><div>Fu</div><div>funnel</div></div>	<div><div></div><div>Ri</div><div>rich picture</div></div>
<div><div></div><div>B</div><div>bar chart</div></div>	<div><div></div><div>Ac</div><div>area chart</div></div>	<div><div></div><div>R</div><div>radar chart cobweb</div></div>	<div><div></div><div>Pa</div><div>parallel coordinates</div></div>	<div><div></div><div>Hy</div><div>hyperbolic tree</div></div>	<div><div></div><div>Cy</div><div>cycle diagram</div></div>	<div><div></div><div>T</div><div>timeline</div></div>	<div><div></div><div>Ve</div><div>venn diagram</div></div>	<div><div></div><div>Mi</div><div>mindmap</div></div>	<div><div></div><div>Sq</div><div>square of oppositions</div></div>	<div><div></div><div>Cc</div><div>concentric circles</div></div>	<div><div></div><div>Ar</div><div>argument slide</div></div>	<div><div></div><div>Sw</div><div>swim lane diagram</div></div>	<div><div></div><div>Gc</div><div>gant chart</div></div>	<div><div></div><div>Pm</div><div>perspectives diagram</div></div>	<div><div></div><div>D</div><div>dilemma diagram</div></div>	<div><div></div><div>Pr</div><div>parameter ruler</div></div>	<div><div></div><div>Kn</div><div>knowledge map</div></div>
<div><div></div><div>Hi</div><div>histogram</div></div>	<div><div></div><div>Sc</div><div>scatterplot</div></div>	<div><div></div><div>Sa</div><div>sankey diagram</div></div>	<div><div></div><div>In</div><div>information lense</div></div>	<div><div></div><div>E</div><div>entity relationship diagram</div></div>	<div><div></div><div>Pt</div><div>petri net</div></div>	<div><div></div><div>Fl</div><div>flow chart</div></div>	<div><div></div><div>Cl</div><div>clustering</div></div>	<div><div></div><div>Lc</div><div>layer chart</div></div>	<div><div></div><div>Py</div><div>minto pyramid technique</div></div>	<div><div></div><div>Ce</div><div>cause-effect chains</div></div>	<div><div></div><div>Tl</div><div>toulmin map</div></div>	<div><div></div><div>Dt</div><div>decision tree</div></div>	<div><div></div><div>Cp</div><div>cpm critical path method</div></div>	<div><div></div><div>Cf</div><div>concept fan</div></div>	<div><div></div><div>Co</div><div>concept map</div></div>	<div><div></div><div>Ic</div><div>iceberg</div></div>	<div><div></div><div>Lm</div><div>learning map</div></div>
<div><div></div><div>Tk</div><div>tukey box plot</div></div>	<div><div></div><div>Sp</div><div>spectrogram</div></div>	<div><div></div><div>Da</div><div>data map</div></div>	<div><div></div><div>Tp</div><div>treemap</div></div>	<div><div></div><div>Cn</div><div>cone tree</div></div>	<div><div></div><div>Sy</div><div>system dyn./ simulation</div></div>	<div><div></div><div>Df</div><div>data flow diagram</div></div>	<div><div></div><div>Se</div><div>semantic network</div></div>	<div><div></div><div>So</div><div>soft system modeling</div></div>	<div><div></div><div>Sn</div><div>synergy map</div></div>	<div><div></div><div>Fo</div><div>force field diagram</div></div>	<div><div></div><div>Ib</div><div>ibis argumentation map</div></div>	<div><div></div><div>Pr</div><div>process event chains</div></div>	<div><div></div><div>Pe</div><div>pert chart</div></div>	<div><div></div><div>Ev</div><div>evocative knowledge map</div></div>	<div><div></div><div>V</div><div>Yee diagram</div></div>	<div><div></div><div>Hh</div><div>heaven 'n' hell chart</div></div>	<div><div></div><div>I</div><div>infomural</div></div>

Cy

Process Visualization

Hy

Structure Visualization




**Overview
Detail**































Detail AND Overview

< >

Divergent thinking

> <

Convergent thinking


 Su supply demand curve	 Pc performance charting	 St strategy map	 Oc organisation chart	 Ho house of quality	 Fd feedback diagram	 Ft failure tree	 Mq magic quadrant	 Ld life-cycle diagram	 Po porter's five forces	 S s-cycle	 Sm stakeholder map	 Is ishikawa diagram	 Tc technology roadmap
 Ed edgeworth box	 Pf portfolio diagram	 Sg strategic game board	 Mz mintzberg's organigraph	 Z zwick's morphological box	 Ad affinity diagram	 De decision discovery diagram	 Bm bcg matrix	 Stc strategy canvas	 Vc value chain	 Hy hype-cycle	 Sr stakeholder rating map	 Ta taps	 Sd spray diagram

Note: Depending on your location and connection speed it can take some time to load a pop-up picture.

© Ralph Lengler & Martin J. Eppler; www.visual-literacy.org


version 1.5

For example...



**Statistical
process
control**

Lung Cancer Mortality in Under 75s, 2004-06




Source: Compendium of Clinical and Health Indicators, 1
Note: Population is adjusted due to Standardisation Calc

**Funnel
plots**

PCT Name	updated	Year	East of England	Bedfordshire	Cambridgeshire	East & North Hertfordshire	Great Yarmouth & Luton	Mid Essex	North Essex	North East Essex	North Essex	South Essex	South East Essex	West Essex	West Essex	West Essex
Improving lives, saving lives (Pledge II)																
Percentage of eligible children in Reception with height and weight measurements	Y	2007/08	87.9	93.6	87.1	95.0	96.1	91.1	76.7	90.9	89.1	89.5	84.2	90.0	90.3	88.8
Percentage of obese children in Reception	Y	2007/08	9.3	8.7	8.9	8.7	10.4	10.6	8.7	9.1	9.0	12.6	8.3	10.8	8.8	8.2
Percentage of eligible children in Year 6 with height and weight measurements	Y	2007/08	84.0	88.9	83.2	86.8	89.7	92.5	88.4	88.5	80.3	87.0	83.2	87.4	85.7	86.5
Percentage of obese children in Year 6	Y	2007/08	16.7	15.1	17.0	16.3	16.6	20.5	15.7	18.0	15.5	19.1	16.9	17.5	14.4	17.6
Percentage of women smoking at delivery*	Y	2007/08	14.3	19.8	11.6	14.6	DNR	17.6	10.5	13.1	20.4	16.1	14.0	11.3	13.8	14.4
Percentage of maternities with known smoking status	Y	2007/08	98.2	95.8	100.0	100.0	DNR	96.0	95.1	95.5	99.7	100.0	98.8	98.6	99.1	97.2
Percentage of mothers known to initiate breastfeeding*	Y	2007/08	73.0	65.3	79.0	73.8	68.1	DNR	73.8	73.9	57.5	70.3	69.8	73.9	75.8	76.8
Percentage of maternities with known breastfeeding status	Y	2007/08	98.1	95.2	100.0	99.0	97.6	DNR	99.2	99.9	100.0	97.8	98.1	99.4	95.6	99.3
Number of tests for Chlamydia per 100,000 aged 15-24	Y	2008/09 Q2	130.4	180.1	121.4	140.1										
Teenage conception rates per 1,000 females aged 15-17		2004-06	22.8	22.6	24.9	27.8										
Percentage of children who have had the first dose of MMR by their second birthday	Y	2007/08	84	95.7	94.0	98.4										

Tartan rugs



**Interactive
dashboards**

Profiles...

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period		
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range			High- est	
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010	
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011	
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011	
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010	
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010	
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010	
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010	
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010	
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011	
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011	
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011	
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011	
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011	
Specialist Team	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11	
	15	Peer review: Proportion of peer review indicators met	SA	85%			89%					NCPR	2010/11
	16	Peer review: are there immediate risks? (4)	SA	No								NCPR	2010/11
	17	Peer review: are there serious concerns? (4)	SA	No								NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%		100%	NLCA	2011	
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer	406				293	0		853	CWT	2010/11	
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%		93%	NLCA	2011	
	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%		100%	NLCA	2011	
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%		79%	NLCA	2011	
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		100%	NLCA	2011	
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		97%	HES	2011	
Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2	
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2	
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12	
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12	
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2	
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011	
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011	
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011	
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011	
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011	
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011	
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.49	NLCA	2011	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12	
	40	Number of survey questions and % of those questions scoring red and green (7)	% Red	0	n/a			0%		78%	CPES	2011/12	
	% Green		0	n/a			0%		69%	CPES	2011/12		

Profiles... why?

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate				Trust rate or percentage compared to England				Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range		High- est		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41			588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				191	1			585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0			31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%			75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%			100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%			46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%			34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%			72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%			100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%			68%	NLCA	2011
	11	Number a										NLCA	2011
	12	Number a										NLCA	2011
	13	Proportion										NLCA	2011
Specialist Team	14	Peer review										NCPR	2010/11
	15	Peer review										NCPR	2010/11
	16	Peer review										NCPR	2010/11
	17	Peer review										NCPR	2010/11
	18	Number a										NLCA	2011
Throughput and pathology	19	Number c										CWT	2010/11
	20	Number a										NLCA	2011
	21	Number a										NLCA	2011
	22	Number a										NLCA	2011
	23	Number a										NLCA	2011
Waiting times	24	Estimated										HES	2011
	25	Q2 2012/										CWT	2012/13 Q2
	26	Q2 2012/										CWT	2012/13 Q2
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%			46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%			76%	CWT	2011/12
Practice	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%			100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%			100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%			38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%			45%	NLCA	2011
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%			100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%			100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%			100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%			68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57			1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40			2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%			100%	CPES	2011/12
	40	% Red	0	n/a				0%			78%	CPES	2011/12
	41	Number of survey questions and % of those questions scoring red and green (7)		n/a				0%			69%	CPES	2011/12

- Assess and benchmark a wide range of information at organisation level
- Allows a 'at a glance' assessment of an organisation

Lung profiles – process

- Aim: Benchmark and assess trust/MDT for commissioning & clinical review
- Published March 2013 (developed from similar Breast/Colorectal profiles published Dec 2011, Feb 2013)
- Data – cancer registry, CWT, NLCA, CPES, HES, Peer Review
- Roughly half indicators generic, half specialist.
- Specialist indicators largely drawn from NLCA
- Indicators Incorporate Clinical Lines of Enquiry
- A NCIN / Thames Cancer Registry co-production
- Hosted in the Cancer Commissioning Toolkit

Profile anatomy

Section	#	Indicator	Percentage or rate				Trust rate or percentage compared to England				Source	Period
			No. of patients/cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Lowest	Range	Highest		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41		588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				19	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0		31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011
	14	Peer review: Doe									NCPR	2010/11
Specialist Team	15	Peer review: Pro										
	16	Peer review: are										
	17	Peer review: are										
Throughput and pathology	18	Number and prop										
	19	Number of urgent										
	20	Number and prop										
	21	Number and prop										
	22	Number and prop										
Waiting times	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		97%	HES	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12
Practice	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011
Outcomes and Recovery	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.1	0.57		1.49	NLCA	2011
Patient Experience - CPES (8)	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.1	0.40		2.67	NLCA	2011
	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)	0	n/a				0%		78%	CPES	2011/12
	41			n/a				0%		69%	CPES	2011/12

**Indicator
descriptions
(41)**

**Numbers,
rates, and
comparators**

**Spine chart &
range of data**

**Sources &
Dates**

Profile anatomy

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010							588	NCDR	2010
	2	Number of NLCA patients - lung cancer							585	NLCA	2011
	3	Number of NLCA patients - mesothelioma							31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+							75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British							46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)							34%	NCDR	2010
	8	Male patients (from #1)							72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned							100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned							68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned							30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	80%	2%	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)	CA	Var						NCPR	2010/11
	15	Pe								NCPR	2010/11
Specialist Team	16	Pe								NCPR	2010/11
	17	Pe								NCPR	2010/11
Throughput and pathology	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	70%	0%	100%	NLCA	2011
	19	Number of urgent GP referrals for suspected cancer	406				293	0	853	CWT	2010/11
	20	Number and proportion of pati							93%	NLCA	2011
	21	Number and proportion of pati							100%	NLCA	2011
	22	Number and proportion of pati							79%	NLCA	2011
	23	Number and proportion of pati							100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	97%	HES	2011
Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	98%	92%	98%	97%	88%	100%	CWT	2012/13 Q2
	26	Q2 20								CWT	2012/13 Q2
	27	Urgen								CWT	2011/12
	28	Cases								CWT	2011/12
Practice	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	75%	100%	99%	91%	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC							38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC							45%	NLCA	2011
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and I							100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy							100%	NLCA	2011
	35	No. and proportion of patients (from #2) with stage IIIB/IV, PS 0-1 and confirmed SCLC receiving chemotherapy	28	58%	44%	74%	55%	0%	100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appoi							68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for morta							1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted oc							2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)							100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)							78%	CPES	2011/12

Size – no. patients diagnosed

**Patient demographics
(including stage/PS)**

Specialist team – Peer Review concerns and CNS coverage

Throughput and pathology – patient breakdown

Waiting times performance and conversion/detection rates

Clinical practice

Outcomes and recovery

Patient Experience

Profiles – detail (1)

Section	#	Indicator
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)
	2	Number of NLCA patients - lung cancer
	3	Number of NLCA patients - mesothelioma
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+
	5	Patients (from #1) with recorded ethnicity
	6	Patients (from #5) with recorded ethnicity which is not White-British
	7	Patients (from #1) who are Income Deprived (2)
	8	Male patients (from #1)
	9	Number and proportion of patients (from #2) with a stage assigned
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned
	13	Proportion of patients (from #2) with a Performance Status assigned

Profiles – detail (2)

Specialist Team	14	Peer review: Does the specialist team have full membership? (3)
	15	Peer review: Proportion of peer review indicators met
	16	Peer review: are there immediate risks? (4)
	17	Peer review: are there serious concerns? (4)
	18	Number and proportion of patients (from #2) seen by CNS (5)
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer
	20	Number and proportion of patients (from #2) with confirmed NSCLC
	21	Number and proportion of patients (from #2) with confirmed SCLC
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis
	24	Estimated proportion of tumours with emergency presentations [experimental]

Profiles – detail (3)

Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]
	29	Q2 2012/13: First treatment began within 31 days of decision to treat
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy

Profiles – detail (4)

Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	
	40	Number of survey questions and % of those questions scoring red and green (7)	% Red
	41		% Green

Lung profiles overview

- Contains many relevant process, clinical, and outcome indicators – but new data gives new opportunities
- (The NLCA adds a great deal of clinical value)
- Profile format is strong at assessing and benchmarking organisations (but not the whole story)

Specialist Lung profiles?

- Use a profile format to assess and benchmark organisations (?)
- Some challenges:
 - Only include cases referred for surgery?
 - Can we separate local/specialist cases at same provider?
 - Need a good understanding of how the pathway is represented in the data
- What are the important process, clinical and outcome variables?



www.ncin.org.uk